Bristol Myers Squibb

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, that specializes in the development of an automated platform for producing and characterizing antibodies. Founded in 2019, BigHat utilizes an AI-guided protein therapeutic platform that combines a wet lab with machine learning techniques. This integration allows drug developers to engineer antibodies and biotherapeutics with enhanced functions and improved biophysical properties. The company's innovative design capabilities aim to create safer and more effective treatments for patients facing complex diseases.

Owkin is an artificial intelligence company founded in 2016, with headquarters in New York and an additional office in Paris. The company focuses on developing machine learning software for medical research, enabling researchers to test AI models on distributed data. Owkin's offerings include Owkin Lab, which facilitates data connectivity by therapeutic area; Owkin Loop, which provides validated and packaged models; and a comprehensive software stack for full-stack services. The company currently has 30 live models and an additional 40 in development. Owkin aims to empower medical researchers in hospitals, universities, and pharmaceutical companies to better understand variations in drug efficacy among patients, enhance the drug development process, and identify optimal treatments for individual patients, ultimately improving treatment outcomes. The company is supported by various investors and has a scientific board to guide its research initiatives.

Transition Bio, Inc. is a biotechnology company that specializes in the discovery, analysis, and modulation of biological condensates. Established in 2020 and headquartered in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom, the company has developed a unique platform known as Condensomics. This hypothesis-free drug discovery and diagnostics technology allows for expansive opportunities in drug development by leveraging the intricate properties of biological condensates. Transition Bio's innovative approach aims to advance the understanding and application of these biological structures in the field of medicine.

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer. The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States.

Octant, Inc. engages in engineering biology to design multi-targeted small molecule drug leads for complex diseases. Its polypharmacology discovery engine generates multi-receptor pathway data and predictive insights to inform rational drug design. The company also engineers biology using living cells as high-throughput signal networks to map, measure, and model chemical structures against G protein-coupled receptors (GPCRs). The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Octant, Inc. engages in engineering biology to design multi-targeted small molecule drug leads for complex diseases. Its polypharmacology discovery engine generates multi-receptor pathway data and predictive insights to inform rational drug design. The company also engineers biology using living cells as high-throughput signal networks to map, measure, and model chemical structures against G protein-coupled receptors (GPCRs). The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.

Silagene is a biotech company developing technology designed to facilitate the creation of U1 adaptors with therapeutic potential. The company's technology overcomes the limitations of gene silencing technologies, enabling doctors to to treat patients with various types of cancers. It was founded in 2008 and is based in Hillsborough, New Jersey, United States.

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.

Compugen is an IT solutions and service provider.

Clade Therapeutics is a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem-cell-based medicines.

Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor designed to target a critical microRNA that regulates harmful changes in the heart resulting from stress or injury. Cardior Pharmaceuticals is positioned as a planned academic spin-off, emphasizing innovative approaches to address significant cardiovascular health challenges.

IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.

Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preserve cognition in patients.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, founded in 2008. The company has developed an innovative platform known as the CIVO arrayed microinjection system, which allows for the simultaneous evaluation of multiple drugs or drug combinations directly within a patient's tumor. This technology assesses efficacy, resistance, and drug synergies in the tumor's native microenvironment, overcoming the limitations of traditional systemic drug administration. By employing its clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, thereby streamlining drug development. Additionally, the technology facilitates the identification of effective drug combinations and targets using RNA interference, providing a more accurate measurement of treatment efficacy tailored to individual patient responses.

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, focused on developing targeted therapies for rare cardiovascular diseases, particularly genetic heart conditions. Established in 2012, the company is dedicated to addressing the medical needs of patients with heritable cardiomyopathies and genetically-driven heart failure resulting from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). MyoKardia is also developing Danicamtiv, a small molecule that has completed early-stage trials for dilated cardiomyopathy. Additionally, the company has several preclinical programs, including MYK-224 and ACT-1, aimed at treating various forms of diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.

Autobahn Therapeutics, Inc. develops small molecule therapies for the treatment of central nervous system (CNS) disorders. The company develops ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS), and adrenomyeloneuropathy (AMN). Autobahn Therapeutics, Inc. was formerly known as Llama Therapeutics, Inc. and changed its name to Autobahn Therapeutics, Inc. in December 2019. The company was incorporated in 2017 and is based in San Diego, California.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Compugen is an IT solutions and service provider.

Avera PACE, a division of Avera Health, is a regional group-purchasing organization with a strong presence in the upper Midwest states but serves clients from all over the United States. Whether your business is located in a metro or rural community – you can benefit from access to Avera PACE’s contracts, services, and products at the lowest possible cost through collaboration, utilization, and continuous improvement.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.

TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Jefferson Health System

Akamis Bio is a biotechnology company dedicated to developing innovative gene-based immuno-oncology therapies for cancer treatment. The company focuses on discovering and advancing a range of candidate therapies, including those utilizing its proprietary T-SIGn virus platform, which allows for systemic delivery while exerting localized effects within tumors. Akamis Bio aims to become a leader in cancer gene therapy, emphasizing the importance of creating medicines that provide tangible benefits to patients. The company is actively engaged in both early and clinical stage development of its therapies and seeks to establish strategic partnerships with other leaders in the immuno-oncology field to enhance its product offerings and accelerate the availability of its treatments.

The UNC Center for Aging and Health focuses on delivering high-quality clinical care to older adults while also bridging the gap between families, caregivers, and community resources. The center emphasizes the importance of training not only geriatricians but also a variety of healthcare providers, including dentists, pharmacists, cardiologists, and oncologists, in best practices of geriatric medicine. This training is rooted in research, prioritizes patient needs, and is delivered with compassion. Additionally, as part of the University of North Carolina School of Medicine, the center is committed to improving health and well-being in North Carolina and beyond through excellence in patient care, education, and research, fostering a diverse and respectful environment for faculty, staff, and learners.

IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor designed to target a critical microRNA that regulates harmful changes in the heart resulting from stress or injury. Cardior Pharmaceuticals is positioned as a planned academic spin-off, emphasizing innovative approaches to address significant cardiovascular health challenges.

Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.

Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the Karolinska Institute Science Park in Stockholm, Sweden. Based on mounting research pointing to IL-8 being an important driver of malignant tumors, HuMax-IL8 was acquired from Genmab A/S and taken into development by Cormorant. HuMax-IL8, is a fully human monoclonal antibody

Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.

Padlock is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock was founded by scientists at The Scripps Research Institute and members of the Atlas Venture Life Sciences Team. Padlock's investors include Atlas Venture, Johnson & Johnson, and MS Ventures. Padlock is a seed company operating out of the Atlas Venture office in Cambridge MA.

Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.

Flexus is a privately-held biopharmaceutical company focused on the creation, development, and commercialization of novel anti-cancer therapeutics through an innovative application of unexploited insights in immunology. Founded in 2013, Flexus is headquartered in San Carlos, California.

We are using induced pluripotent stem cells for drug discovery and development. Focused on neurodegenerative diseases such as SMA, ALS and Parkinson's, and other major unmet medical needs.

Amylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs. Develops a line of diagnostic and therapeutic products for diabetics. Working towards a cure for diabetes by challenging science, changing lives. Amylin employees are dedicated in their ability to "think outside the box". Because of our commitment of constantly finding newer and better ways to treat diabetes, we come to work each day feeling like we CAN make a difference in our world.

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

CareDx is a molecular diagnostics company headquartered in Brisbane, California, established in 2000. It specializes in developing diagnostic assays that leverage advanced genomics technologies to provide clinically actionable insights into a patient's immune status. The company’s flagship product, AlloMap Molecular Expression Testing, is designed for the management of heart transplant patients, aiding in the assessment of transplant rejection. Beyond heart transplants, CareDx is exploring the potential application of its proprietary molecular expression technology for other organ transplants and conditions related to immune system activity, including autoimmune and chronic inflammatory diseases. The company continues to innovate and develop additional products to enhance patient care in transplantation and related fields.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners.

ConvaTec has been a pioneer in developing and marketing innovative wound therapeutics and ostomy care products that have helped improve the lives of millions of people worldwide. ConvaTec continues to be at the forefront of the movement to change the way health care professionals are managing chronic and acute wounds, emphasizing the principles of advanced wound healing and evidence-based medicine. From its headquarters in Skillman, New Jersey, the company oversees more than 3,500 employees in 91 countries serving patients and their healthcare professionals on six continents.

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

DuPont Pharmaceuticals Company engages in the research, development, and delivery of pharmaceuticals that are used in the treatment of HIV, cardiovascular disease, central nervous system disorders, cancer, and inflammatory diseases.

Mead Johnson Nutrition manufactures and sells infant formula, children’s nutrition, and other nutritional products. It offers routine infant formula products as infant’s source of nutrition and supplement to breastfeeding under Enfamil Premium, Enfamil A+, Enfalac Premium, and Enfapro A+ names; and solutions for feeding tolerance problems, including spit-up, fussiness, gas, and lactose intolerance under Enfamil Gentlease, Enfamil A.R., Enfamil ProSobee, and Enfamil LactoFree names. Mead Johnson Nutrition also provides specialty formula products, such as Nutramigen for cow’s milk protein allergies, and Puramino, an amino acid formula for severe cow’s milk protein allergies or other food allergies; Enfamil Premature for premature and low birth weight infants; EnfaCare, a hypercaloric formula for premature babies at home; and medical foods for nutritional management of individuals with rare, inborn errors of metabolism comprising maple syrup urine disease under Mead Johnson BCAD and Mead Johnson Phenyl-Free names. Moreover, Mead Johnson Nutrition offers children’s nutrition products to meet nutritional needs of toddlers and older children under Enfagrow, Sustagen, and Lactum names, as well as milk modifiers under ChocoMilk and Cal-C-Tose names. Further, it provides various other products that comprise pre-natal and post-natal nutritional supplements for expectant and nursing mothers under Expecta and EnfaMama names; pediatric vitamin products that provide multivitamins and iron supplements for infants under Enfamil Poly-Vi-Sol name; and Enfalyte, an oral electrolyte solution for infants and children to replace electrolytes and water to enable restore hydration. Mead Johnson Nutrition markets its products to mothers, health care professionals, and retailers in approximately 50 countries in Asia, North America, Latin America, and Europe. Edward Mead Johnson founded it in 1905, with its headquarters in Glenview in Illinois, now as a subsidiary of Reckitt Benckiser Group.